5
Solvay Pharma India Ltd(merged)
532447 BSE
This stock has been delisted or merged and is no longer actively traded.
Solvay Pharma India Ltd(merged)
Healthcare Delisted BSE: 532447 Pharmaceuticals & Biotechnology
This stock has been delisted or merged and is no longer actively traded.
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
5- Company is almost debt free.
- Company has delivered good profit growth of 22.8% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 33.5%
- Company has been maintaining a healthy dividend payout of 31.1%
- Debtor days have improved from 25.1 to 18.6 days.
Growth Rate
Revenue Growth
22% higher than
3Y
Net Income Growth
30% higher than
3Y
Quarterly Results
| Particulars | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 19.83 | 11.88 | 30.66 | 16.09 | 11.5 | 5.51 | 15.59 | 10.22 | 8.34 | 8.04 | 16.44 | 8.92 | 10.53 |
| Expenses | 23.73 | 19.16 | 25.42 | 15.54 | 14 | 9.04 | 14.21 | 13.06 | 11.49 | 14.84 | 16.31 | 10.18 | 10.51 |
| Operating Profit | -3.9 | -7.28 | 5.24 | 0.55 | -2.5 | -3.53 | 1.38 | -2.84 | -3.15 | -6.8 | 0.13 | -1.26 | 0.02 |
| OPM % | -19.67% | -61.28% | 17.09% | 3.42% | -21.74% | -64.07% | 8.85% | -27.79% | -37.77% | -84.58% | 0.79% | -14.13% | 0.19% |
| Other Income | 0.75 | 4.3 | 0.72 | 3.01 | 3.5 | 0.98 | 1.61 | 2.3 | 1.05 | 4.99 | 2.2 | -0.68 | 0.54 |
| Interest | 0.01 | 0.44 | 0.13 | 0.08 | 0.08 | 0.25 | 0.1 | 0.09 | 0.11 | 0.26 | 0.08 | 0.11 | 0.06 |
| Depreciation | 0.42 | 0.8 | 0.48 | 0.48 | 0.52 | 0.53 | 0.5 | 0.51 | 0.45 | 0.59 | 0.44 | 0.52 | 0.06 |
| PBT | -3.58 | -4.22 | 5.35 | 3 | 0.4 | -3.33 | 2.39 | -1.14 | -2.66 | -2.66 | 1.81 | -2.57 | 0.44 |
| Tax % | -25.98% | -21.33% | 15.33% | -31% | 290% | -44.44% | 12.97% | 21.93% | 0% | -219.92% | -96.13% | 47.47% | -22.73% |
| Net Profit | -2.65 | -3.32 | 4.53 | 3.93 | -0.76 | -1.85 | 2.09 | -1.4 | -2.65 | 3.19 | 3.55 | -3.8 | 0.54 |
| EPS in Rs | -1.79 | -2.24 | 3.06 | 2.66 | -0.51 | -1.25 | 1.41 | -0.95 | -1.79 | 2.16 | 2.4 | -2.57 | 0.36 |
Profit & Loss
| Particulars | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 |
|---|---|---|---|---|---|---|
| Sales | 130 | 144 | 167 | 202 | 242 | 295 |
| Expenses | 99 | 113 | 123 | 156 | 183 | 222 |
| Operating Profit | 30 | 31 | 44 | 46 | 59 | 73 |
| OPM % | 23% | 21% | 26% | 23% | 24% | 25% |
| Other Income | 3 | 4 | 4 | 6 | 5 | 6 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 5 | 5 | 5 | 1 | 3 | 3 |
| PBT | 28 | 30 | 43 | 50 | 61 | 76 |
| Tax % | 36% | 37% | 34% | 35% | 34% | 33% |
| Net Profit | 18 | 19 | 28 | 33 | 40 | 51 |
| Div. Payout % | 17% | 22% | 72% | 27% | 41% | 25% |
Balance Sheet
| Particulars | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 |
|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 63 | 77 | 82 | 104 | 125 | 161 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 21 | 26 | 32 | 48 | 41 | 54 |
| Total Liabilities | 89 | 108 | 119 | 157 | 172 | 220 |
| Fixed Assets | 10 | 7 | 4 | 2 | 38 | 36 |
| CWIP | 0 | 0 | 0 | 35 | 0 | 0 |
| Investments | 7 | 14 | 40 | 17 | 16 | 37 |
| Other Assets | 72 | 87 | 74 | 103 | 118 | 148 |
| Total Assets | 89 | 108 | 119 | 157 | 172 | 220 |
Cash Flow
| Particulars | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 |
|---|---|---|---|---|---|---|
| Operating | 17 | 15 | 27 | -7 | 70 | 27 |
| Investing | -6 | -6 | -24 | 1 | -9 | -17 |
| Financing | -3 | -4 | -19 | -12 | -15 | -12 |
| Net Cash Flow | 8 | 6 | -17 | -17 | 46 | -2 |
| Free Cash Flow | 17 | 14 | 24 | -34 | 59 | 26 |
| CFO/OP | 91 | 91 | 92 | 27 | 152 | 74 |
Ratios
| Particulars | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 |
|---|---|---|---|---|---|---|
| Debtor Days | 36 | 36 | 36 | 33 | 24 | 19 |
| Inventory Days | 113 | 136 | 118 | 240 | 116 | 165 |
| Days Payable | 94 | 107 | 89 | 134 | 74 | 87 |
| Cash Conversion Cycle | 56 | 65 | 66 | 140 | 66 | 96 |
| Working Capital Days | 44 | 47 | 34 | 82 | 33 | 49 |
| ROCE % | — | 39% | 51% | 51% | 50% | 51% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Solvay Pharma India Ltd(merged) insights
28 extracted metrics + investor summaries across FY05–FY10.
Documents
1
Announcement under Regulation 30 (LODR)-Resignation of Director
28 Feb - Executive Director Vindamuri Giri Raj (DIN:09719564) resigned effective 28 Feb 2026. 28 Feb - Executive Director Vindamuri Giri Raj (DIN:09719564) resigned effective 28 Feb 2026.
2
Announcement under Regulation 30 (LODR)-Change in Management
28 Feb - Executive Director Vindamuri Giri Raj resigned effective 28 February 2026, citing personal reasons. 28 Feb - Executive Director Vindamuri Giri Raj resigned effective 28 February 2026, citing personal reasons.
4
Board Meeting Outcome for OUTCOME OF BOARD MEETING
13 Feb - Q3 FY26 results approved: revenue Rs1,053.28L, PAT Rs269.68L; limited review completed. 13 Feb - Q3 FY26 results approved: revenue Rs1,053.28L, PAT Rs269.68L; limited review completed.
Frequently Asked Questions about Solvay Pharma India Ltd(merged)
What does Solvay Pharma India Ltd(merged) do?
Solvay Pharma India Limited(merged), incorporated in India, listed on the Bombay Stock Exchange, the company is engaged in tablets, capsules, syrups, etc.
Where is Solvay Pharma India Ltd(merged) (532447) listed?
Solvay Pharma India Ltd(merged) trades under code 532447 on the BSE.
Which sector does Solvay Pharma India Ltd(merged) belong to?
Solvay Pharma India Ltd(merged) is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
Company Information
Solvay Pharma India Limited(merged), incorporated in India, listed on the Bombay Stock Exchange, the company is engaged in tablets, capsules, syrups, etc.
Website solvaypharma.co.in
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/532447.md for Solvay Pharma India Ltd(merged): company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.